FLT3 and neoplasm: Primary resistance is linked to intrinsic tumor cell factors, including the overexpression of CYP3A4 and the activation of FLT3 ligand; secondary resistance is associated with de novo FLT3 mutations and the aberrant activation of downstream signaling pathways (Ruglioni et al., 2024).